Physician profile
Stephen W Nesbit
NPI 1356401343
$1,089.16
in general payments reported to CMS, 2019-2025
18 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.55 · 2024: $523 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.91 | 2024-2025 | |
| Novo Nordisk INC | $198.02 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $113.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.86 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $72.12 | 2024-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $61.32 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $31.31 | 2024-2025 | |
| Amgen INC. | $27.70 | 2025 | Otezla, Repatha, Evenity |
| Inari Medical, INC. | $25.55 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $20.81 | 2025 | Lumryz |
| Sumitomo Pharma America, INC. | $19.70 | 2025 | Gemtesa |
| Recor Medical INC | $17.79 | 2024 | Paradise Renal Denervation System |
| Janssen Pharmaceuticals, INC | $17.68 | 2025 | Spravato |
| Corcept Therapeutics | $17.65 | 2024 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2024 | Trintellix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $16.74 | 2025 | Veozah |
| Sanofi Pasteur INC. | $15.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.25 | 2024 | Spiriva Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nesbit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.